Top

Archives of Gynecology and Obstetrics

Published in:

01-09-2018 | Maternal-Fetal Medicine

sFlt-1/PlGF ratio for the prediction of the time of delivery

Authors: Oliver Graupner, Silvia M. Lobmaier, Javier U. Ortiz, Anne Karge, Bettina Kuschel

Published in: Archives of Gynecology and Obstetrics | Issue 3/2018

Abstract

Purpose

The soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio has been shown to be a useful parameter for the diagnosis and prediction of preeclampsia (PE). An increased sFlt-1/PlGF ratio can be closely linked to the need to deliver. The aim of the study was to examine the mean time until delivery (MTUD) in pregnant women with a strongly increased sFlt-1/PlGF ratio.

Methods

From 2010 to 2018, the sFlt-1/PlGF ratio was determined in 995 singleton pregnancies with diagnosis or suspicion of PE/HELLP syndrome and/or intrauterine growth restriction (IUGR). MTUD of patients with a value above 655 in < 34 weeks of gestation (group 1: n = 13) and above 201 in ≥ 34 weeks of gestation (group 2: n = 15) was calculated. Patients with a value > 85 but < 655 in < 34 weeks of gestation (group 3: n = 70) and a value > 110 but < 201 (group 4: n = 44) in ≥ 34 weeks of gestation acted as controls.

Results

28 pregnant women with severely elevated sFlt-1/PlGF ratio and 114 controls were included. In group 1, MTUD was longer compared to group 2 without reaching statistical significance (96.7 h ± 132.2 vs. 47.7 h ± 44, p = 0.222). In pregnancies < 34 weeks of gestation (early onset), MTUD was significantly longer in group 3 compared to group 1 (361 h ± 317.3 vs. 96.7 h ± 132.2, p < 0.001). In pregnancies ≥ 34 weeks of gestation (late onset), MTUD was significantly longer in group 4 compared to group 2 (123.6 h ± 139.2 vs. 47.7 h ± 44, p = 0.002).

Conclusions

The sFlt-1/PlGF ratio is suitable for decision-making regarding close monitoring of high-risk patients and need for lung maturation. However, for planning of delivery itself further prospective interventional studies are required to define its role as outcome predictor.

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350(7):672–683CrossRefPubMed

Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA (2012) Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125:911–919CrossRefPubMedPubMedCentral

Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206:58.e1–8

Gomez-Arriaga PI, Herraiz I, Lopez-Jimenez EA, Escribano D, Denk B, Galindo A (2014) Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset preeclampsia. Ultrasound Obstet Gynecol 43:525–532CrossRefPubMed

Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W, Verlohren S (2014) The importance of repeated measurements of the sFlt1/PLGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med 42(1):61–68CrossRefPubMed

Lobmaier SM, Figueras F, Mercade I, Perello M, Peguero A, Crovetto F, Ortiz JU, Crispi F, Gratacós E (2014) Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late-pregnancy small-for-gestational-age fetuses. Ultrasound Obstet Gynecol 43(5):533–540CrossRefPubMed

ACOG Committee on Obstetric Practice (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Int J Gynaecol Obstet 77(1):67–75CrossRef

American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy (2013) Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122(5):1122–1131CrossRef

015/018—S1-Leitlinie: Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen aktueller Stand: 12/2013. http://www.awmf.org/uploads/tx_szleitlinien/015018l_S1_Diagnostik_Therapie_hypertensiver_Schwangerschaftserkrankungen_2014-verlaengert.pdf

10.

Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM (2013) The definition of severe and earlyonset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens 3(3):44–47CrossRefPubMed

11.

Weinstein L (1982) Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 142:159–167CrossRefPubMed

12.

Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, Silver RM, Wynia K, Ganzevoort W (2016) Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol 48:333–339CrossRefPubMed

13.

Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, Chantraine F, Klein E, Lapaire O, Llurba E, Ramoni A, Vatish M, Wertaschnigg D, Galindo A (2015) Implementation of the sFlt1/PlGF ratio for prediction and diagnosis of preeclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 45:241–246CrossRefPubMedPubMedCentral

14.

Lees CC, Marlow N, van Wassenaer-Leemhuis A, Arabin B, Bilardo CM, Brezinka C, Calvert S, Derks JB, Diemert A, Duvekot JJ, Ferrazzi E, Frusca T, Ganzevoort W, Hecher K, Martinelli P, Ostermayer E, Papageorghiou AT, Schlembach D, Schneider KT, Thilaganathan B, Todros T, Valcamonico A, Visser GH, Wolf H, TRUFFLE study group (2015) 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 385(9983):2162–2172CrossRefPubMed

15.

Klein E, Schlembach D, Ramoni A, Langer E, Bahlmann F, Grill S, Schaffenrath H, van der Does R, Messinger D, Verhagen-Kamerbeek WD, Reim M, Hund M, Stepan H (2016) Influence of the sFlt-1/PlGF Ratio on Clinical Decision-Making in Women with Suspected Preeclampsia. PLoS One 11(5):e0156013CrossRefPubMedPubMedCentral

16.

Barton JR, Sibai BM (2017) Biomarkers for prediction, risk stratification, and ruling out preeclampsia: what are the appropriate goals and objectives? Am J Perinatol 34(4):415–418PubMed

Title: sFlt-1/PlGF ratio for the prediction of the time of delivery
Authors: Oliver Graupner
Silvia M. Lobmaier
Javier U. Ortiz
Anne Karge
Bettina Kuschel
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 3/2018
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-018-4840-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

sFlt-1/PlGF ratio for the prediction of the time of delivery

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Orlistat induces apoptosis and protective autophagy in ovarian cancer cells: involvement of Akt-mTOR-mediated signaling pathway

Incidence and risk factors for gestational diabetes mellitus in twin versus singleton pregnancies

Ring and Gellhorn pessaries used in patients with pelvic organ prolapse: a retrospective study of 8 years

Esophageal achalasia and pregnancy: own observations in 43 patients and a review of the literature

The influence of seasonal variations on in vitro fertilization and fresh/frozen embryo transfer: a retrospective study

Functional outcomes of nerve-sparing laparoscopic eradication of deep infiltrating endometriosis: a prospective analysis using validated questionnaires